The initial treatment of acute myeloid leukemia is called induction and aims to reduce significantly the number of leukemic cells in the bone marrow. In young adults, this phase comprises several agents, including conventional chemotherapy, monoclonal antibodies, and targeted drugs. Conventionally, induction is delivered as a single block of therapy, the response to which can be appreciated 3–4 weeks after its completion. The authors previously showed that the response to induction can be anticipated by the speed of disappearance of leukemic cells from peripheral blood after four days of therapy. In the AMELIORATE study, the authors aim to personalize the intensity of treatment based on this biomarker, by early intensification of treatment in patients who are predicted to have a poor response.

AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial / Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - ELETTRONICO. - 17:(2021), pp. 3787-3796. [10.2217/fon-2021-0388]

AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial

Mannelli, Francesco;Gianfaldoni, Giacomo;Guglielmelli, Paola;Caporale, Roberto;Vannucchi, Alessandro Maria
2021

Abstract

The initial treatment of acute myeloid leukemia is called induction and aims to reduce significantly the number of leukemic cells in the bone marrow. In young adults, this phase comprises several agents, including conventional chemotherapy, monoclonal antibodies, and targeted drugs. Conventionally, induction is delivered as a single block of therapy, the response to which can be appreciated 3–4 weeks after its completion. The authors previously showed that the response to induction can be anticipated by the speed of disappearance of leukemic cells from peripheral blood after four days of therapy. In the AMELIORATE study, the authors aim to personalize the intensity of treatment based on this biomarker, by early intensification of treatment in patients who are predicted to have a poor response.
2021
17
3787
3796
Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria
File in questo prodotto:
File Dimensione Formato  
future oncology 2021.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 1.43 MB
Formato Adobe PDF
1.43 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1257224
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact